Dangerous Dogs 1996-Current County Agriculture

Historical results of Dangerous Dogs in Pennsylvania. A dangerous dog is one that has: (1) Inflicted severe injury on a human being without provocation on public or private property. (2) Killed or inflicted severe injury on a domestic animal, dog or cat without provocation while off the owner’s property. (3) Attacked a human being without provocation. (4) Been used in the commission of a crime. And the dog has either or both of the following: (1) A history of attacking human beings and/or domestic animals, dogs or cats without provocation. (2) A propensity to attack human beings and/or domestic animals, dogs or cats without provocation. *A propensity to attack may be proven by a single incident. Severe injury is defined as, [3 P.S. § 459-102] “Any physical injury that results in broken bones or disfiguring lacerations requiring multiple sutures or cosmetic surgery.” More information can be found here - https://www.agriculture.pa.gov/Animals/DogLaw/Dangerous%20Dogs/Pages/default.aspx More information on Chapter 27 Regulations - https://www.agriculture.pa.gov/Animals/DogLaw/Dangerous%20Dogs/Documents/Chapter%2027%20Dangerous%20Dogs.pdf PDF's for Chapter 27 and Pennsylvania Dog Laws are attached to the metadata

Buprenorphine Dispensation Data Quarter 3 2016 - Current Quarterly Statewide Health

View quarterly trends in buprenorphine dispensation data. Please note that buprenorphine data received by the PDMP is restricted to prescriptions filled by pharmacies. The PDMP does not collect information on the reason a controlled substance is prescribed, nor does it collect data from substance abuse treatment facilities or dispensing prescribers providing buprenorphine for substance abuse treatment. Buprenorphine is sometimes prescribed off-label for pain. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

Dispensation Data without Buprenorphine Quarter 3 2016 - Current Quarterly County Health

View quarterly trends in opioid dispensation data for all Schedule II-V opioids. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx More information from U.S. Department of Justice https://www.deadiversion.usdoj.gov/schedules/ Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®). Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. Schedule IV Controlled Substances Substances in this schedule have a low potential for abuse relative to substances in Schedule III. Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®). Schedule V Controlled Substances Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

MUNICIPAL_BOUNDARY

Risky Prescribing Measures Quarter 3 2016 - Current Quarterly County & Statewide Health

View quarterly trends in Risky Prescribing Measures, including: o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 4+ Prescribers and 4+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 3+ Prescribers and 3+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the patient’s county of residence. o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence. o Number/Rate of Individuals with > 30 Days of Overlapping Opioid/Benzodiazepine Prescriptions: Number and rate of individuals receiving overlapping opioid and benzodiazepine prescriptions for 30 days or more during a given quarter using state/county populations as denominators. This measure is based on the patients’ county of residence. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

Uninsured Population Census Data CY 2009-2014 Human Services

This data is pulled from the U.S. Census website. This data is for years Calendar Years 2009-2014. Product: SAHIE File Layout Overview Small Area Health Insurance Estimates Program - SAHIE Filenames: SAHIE Text and SAHIE CSV files 2009 – 2014 Source: Small Area Health Insurance Estimates Program, U.S. Census Bureau. Internet Release Date: May 2016 Description: Model‐based Small Area Health Insurance Estimates (SAHIE) for Counties and States File Layout and Definitions The Small Area Health Insurance Estimates (SAHIE) program was created to develop model-based estimates of health insurance coverage for counties and states. This program builds on the work of the Small Area Income and Poverty Estimates (SAIPE) program. SAHIE is only source of single-year health insurance coverage estimates for all U.S. counties. For 2008-2014, SAHIE publishes STATE and COUNTY estimates of population with and without health insurance coverage, along with measures of uncertainty, for the full cross-classification of: •5 age categories: 0-64, 18-64, 21-64, 40-64, and 50-64 •3 sex categories: both sexes, male, and female •6 income categories: all incomes, as well as income-to-poverty ratio (IPR) categories 0-138%, 0-200%, 0-250%, 0-400%, and 138-400% of the poverty threshold •4 races/ethnicities (for states only): all races/ethnicities, White not Hispanic, Black not Hispanic, and Hispanic (any race). In addition, estimates for age category 0-18 by the income categories listed above are published. Each year’s estimates are adjusted so that, before rounding, the county estimates sum to their respective state totals and for key demographics the state estimates sum to the national ACS numbers insured and uninsured. This program is partially funded by the Centers for Disease Control and Prevention's (CDC), National Breast and Cervical Cancer Early Detection ProgramLink to a non-federal Web site (NBCCEDP). The CDC have a congressional mandate to provide screening services for breast and cervical cancer to low-income, uninsured, and underserved women through the NBCCEDP. Most state NBCCEDP programs define low-income as 200 or 250 percent of the poverty threshold. Also included are IPR categories relevant to the Affordable Care Act (ACA). In 2014, the ACA will help families gain access to health care by allowing Medicaid to cover families with incomes less than or equal to 138 percent of the poverty line. Families with incomes above the level needed to qualify for Medicaid, but less than or equal to 400 percent of the poverty line can receive tax credits that will help them pay for health coverage in the new health insurance exchanges. We welcome your feedback as we continue to research and improve our estimation methods. The SAHIE program's age model methodology and estimates have undergone internal U.S. Census Bureau review as well as external review. See the SAHIE Methodological Review page for more details and a summary of the comments and our response. The SAHIE program models health insurance coverage by combining survey data from several sources, including: •The American Community Survey (ACS) •Demographic population estimates •Aggregated federal tax returns •Participation records for the Supplemental Nutrition Assistance Program (SNAP), formerly known as the Food Stamp program •County Business Patterns •Medicaid •Children's Health Insurance Program (CHIP) participation records •Census 2010 Margin of error (MOE). Some ACS products provide an MOE instead of confidence intervals. An MOE is the difference between an estimate and its upper or lower confidence bounds. Confidence bounds can be created by adding the margin of error to the estimate (for the upper bound) and subtracting the margin of error from the estimate (for the lower bound). All published ACS margins of error are based on a 90-percent confidence level.